{"id":35887,"date":"2026-07-30T17:59:03","date_gmt":"2026-07-30T12:29:03","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35887"},"modified":"2026-07-30T17:59:07","modified_gmt":"2026-07-30T12:29:07","slug":"medtech-news-for-nipro-akido-aqua-medical","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical","title":{"rendered":"SIO Urges NCCN to Add Cryoablation to Breast Cancer Guidelines Following ProSense\u00ae FDA Clearance; NIPRO CORPORATION Secures FDA 510(k) Clearance for ELISIO\u2122-HX HDs in the US; Akido Unveils the First AI-Native Health System in the U.S.; MemorialCare Enhances Diagnostic Imaging with Hung Family-Funded 3T MRI Technology; Aqua Medical Treats First U.S. Type 2 Diabetes Patient at UNC Health with Investigational Endoscopic Therapy; NeoCast Delivers Robust Hematoma Resolution and Functional Recovery in Final EMBO-02 First-in-Human Results"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a6b9265bae34\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a6b9265bae34\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\/#ceCure_SIO_Petitions_NCCN_to_Include_Cryoablation_in_Breast_Cancer_Treatment_Guidelines_Citing_IceCures_FDA_Clearance_of_ProSense%C2%AE\" >ceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure&#8217;s FDA Clearance of ProSense\u00ae&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\/#NIPRO_CORPORATION_Received_FDA_510k_Clearance_for_ELISIO%E2%84%A2-HX_Introducing_HDs_to_the_United_States\" >NIPRO CORPORATION Received FDA 510(k) Clearance for ELISIO\u2122-HX, Introducing HDs to the United States&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\/#Akido_Announces_the_First_AI-Native_Health_System_in_the_US\" >Akido Announces the First AI-Native Health System in the US&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\/#Hung_Familys_Generous_Support_Brings_Advanced_3T_MRI_Technology_to_MemorialCares_Long_Beach_Medical_Campus\" >Hung Family&#8217;s Generous Support Brings Advanced 3T MRI Technology to MemorialCare&#8217;s Long Beach Medical Campus&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\/#Aqua_Medical_Treats_First_US_Patient_for_Type_2_Diabetes_at_UNC_Health_Using_Investigational_Through-The-Scope_Endoscopic_Therapy\" >Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\/#Treatment_with_NeoCast_a_Next-Generation_Liquid_Embolic_Results_in_Substantial_Chronic_Subdural_Hematoma_Resolution_and_Functional_Outcome_Gains_in_Final_EMBO-02_First-in-Human_Results\" >Treatment with NeoCast, a Next-Generation Liquid Embolic, Results in Substantial Chronic Subdural Hematoma Resolution and Functional Outcome Gains in Final EMBO-02 First-in-Human Results&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-cecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-guidelines-citing-icecure-s-fda-clearance-of-prosense-nbsp\"><span class=\"ez-toc-section\" id=\"ceCure_SIO_Petitions_NCCN_to_Include_Cryoablation_in_Breast_Cancer_Treatment_Guidelines_Citing_IceCures_FDA_Clearance_of_ProSense%C2%AE\"><\/span><strong>ceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure&#8217;s FDA Clearance of ProSense\u00ae&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 29 July 2026, the Society of Interventional Oncology (SIO) submitted a formal petition to the National Comprehensive Cancer Network (NCCN) seeking the inclusion of percutaneous cryoablation without surgical excision as a Category 2B treatment option for carefully selected patients with low-risk, early-stage breast cancer. The recommendation proposed cryoablation as an alternative to breast-conserving surgery for women aged 70 years and older with specific small, hormone receptor-positive, HER2-negative, clinically node-negative tumors. The petition also recommended considering patients aged 50\u201369 years who were poor candidates for surgery or who declined surgical treatment when cryoablation was combined with whole-breast radiation and endocrine therapy. The SIO supported its request by citing the FDA&#8217;s October 2025 marketing authorization of a cryoablation system for the local treatment of biologically low-risk breast cancer in a defined patient population. The development followed an update to the American Society of Breast Surgeons&#8217; resource guide in March 2026, which had supported cryoablation for appropriately selected patients with low-risk, early-stage breast cancer. Inclusion in the NCCN guidelines was expected to potentially improve clinical awareness and encourage broader consideration of cryoablation, while also supporting future discussions around reimbursement. Overall, the development strengthened the role of minimally invasive cryoablation in breast cancer management and supported growth opportunities for the cryoablation devices and interventional oncology markets.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/cryoablation-devices-market\"><strong>Cryoablation Devices Market Report<\/strong><\/a>,\u201d the global cryoablation devices market is estimated to advance at a <strong>CAGR of 8.8%<\/strong> during the forecast period from 2024 to 2030. The demand for cryoablation devices is primarily being boosted by the rising number of patients suffering from cardiovascular disorders, the increase in the number of patients suffering from chronic disorders such as cancer, the higher availability of customized probes for cryoablation, the increasing technological advancements associated with the cryoablation devices will help in contributing in the overall market growth of the cryoablation devices during the forecast period from 2024-2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nipro-corporation-received-fda-510-k-clearance-for-elisio-hx-introducing-hds-to-the-united-states-nbsp\"><span class=\"ez-toc-section\" id=\"NIPRO_CORPORATION_Received_FDA_510k_Clearance_for_ELISIO%E2%84%A2-HX_Introducing_HDs_to_the_United_States\"><\/span><strong>NIPRO CORPORATION Received FDA 510(k) Clearance for ELISIO\u2122-HX, Introducing HDs to the United States&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 30 July 2026, Nipro Corporation announced that it had received FDA 510(k) clearance for its ELISIO-HX hemodialyzer, supporting the introduction of the technology into the United States. The clearance represented an important regulatory milestone for the company as it expanded its hemodialysis portfolio in the U.S. market. The device was designed as a high-permeability hemodialyzer and was classified by the FDA as a Class II medical device under the high-permeability hemodialysis system category. The regulatory clearance enabled Nipro to strengthen its presence in the U.S. dialysis market and provided healthcare providers with an additional hemodialysis technology option. The development also reflected the continued advancement of dialyzer technologies aimed at supporting effective blood purification during dialysis treatment. Overall, the FDA clearance strengthened Nipro\u2019s position in the U.S. hemodialysis devices market and contributed to the expansion of advanced dialyzer solutions available to dialysis providers.<\/p>\n\n\n\n<p><em>&#8220;Innovation creates its greatest value when it becomes accessible in everyday clinical practice,&#8221; said Tsuyoshi Yamazaki, President &amp; CEO of NIPRO CORPORATION. &#8220;Our ambition is to broaden the number of patients who can benefit from enhanced hemodialysis. With HDs, enabled by ELISIO-HX and our proprietary super high-flux membrane technology, healthcare professionals can enhance hemodialysis using the infrastructure and expertise they already have. FDA clearance represents an important milestone in bringing this approach to patients across the United States.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/haemodialysis-machines-market\"><strong>Hemodialysis Machines Market Report<\/strong><\/a>,\u201d the global hemodialysis machines market was valued at <strong>USD 13.53 billion<\/strong> in 2023, growing at a <strong>CAGR of 4.71%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 17.78 billion<\/strong> by 2030. The increase in demand for Hemodialysis Machines is primarily attributed to the increasing prevalence of kidney disorders such as end-stage kidney disorder, kidney failure, and others. In addition, the constantly increasing old population, high blood pressure, and high diabetes prevalence are also driving factors for Hemodialysis Machines, as old age and diabetic people are more likely to develop kidney disorders. Moreover, technological advancement in the Hemodialysis Machines product pipeline and an increase in product approvals are among the other factors responsible for the growth of the global Hemodialysis Machines market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-akido-announces-the-first-ai-native-health-system-in-the-us-nbsp\"><span class=\"ez-toc-section\" id=\"Akido_Announces_the_First_AI-Native_Health_System_in_the_US\"><\/span><strong>Akido Announces the First AI-Native Health System in the US&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 30 July 2026, Akido announced that it had been developing an AI-native health system in the United States by expanding its proprietary ScopeAI technology across approximately 100 clinics, virtual care services, and field medicine programs. The AI-powered network was expected to provide access to healthcare for nearly 1 million patients across California, New York City, and Rhode Island. ScopeAI was designed to organize patients\u2019 clinical information in real time and provide physicians with an initial diagnostic overview, allowing them to devote more attention to patient care while reducing administrative workloads. The initiative was launched amid growing physician shortages and longer healthcare wait times in the U.S., with the Association of American Medical Colleges projecting a potential shortage of up to 86,000 physicians by 2036. Akido also strengthened its technical leadership, established an AI Clinical Advisory Council, and introduced Akido Medical as the brand for its AI-native clinics. The company reported that its revenue had increased by 300% between 2024 and 2025, highlighting the growing adoption of AI-enabled healthcare delivery models. Overall, the development demonstrated the increasing integration of artificial intelligence into clinical workflows and supported the expansion of the U.S. healthcare AI and digital health markets.<\/p>\n\n\n\n<p><em>&#8220;Doctors are leaving medicine because the system asks them to do more with less every year. ScopeAI removes the administrative weight of the visit and supports investigative intake, so physicians can spend their time on what only a human doctor can do.&#8221; Prashant Samant, CEO and co-founder, Akidol.<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/artificial-intelligence-in-healthcare-market\"><strong>Artificial Intelligence in Healthcare Market Report<\/strong><\/a>,\u201d The global artificial intelligence in healthcare market is expected to increase from <strong>USD 40,809.25 million <\/strong>in 2025 to <strong>USD 861,636.63 million<\/strong> by 2034, reflecting strong and sustained growth. The global artificial intelligence in healthcare market is growing at a <strong>CAGR of 40.40% <\/strong>during the forecast period from 2026 to 2034. The rising prevalence of chronic diseases is increasing the demand for continuous monitoring, early diagnosis, and personalized treatment, which AI-powered tools can efficiently support. At the same time, the accelerating adoption of AI and advanced analytics in healthcare is improving clinical decision-making, operational efficiency, and predictive insights across hospitals and research settings. The expansion of digital health, telemedicine, and remote patient monitoring is further generating large volumes of real-time patient data, enabling AI systems to deliver timely interventions and virtual care solutions. Additionally, advances in machine learning, deep learning, and generative AI are enhancing diagnostic accuracy, drug discovery, and personalized medicine capabilities. Collectively, these factors are significantly driving the growth and transformation of the AI in healthcare market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hung-family-s-generous-support-brings-advanced-3t-mri-technology-to-memorialcare-s-long-beach-medical-campus-nbsp-nbsp\"><span class=\"ez-toc-section\" id=\"Hung_Familys_Generous_Support_Brings_Advanced_3T_MRI_Technology_to_MemorialCares_Long_Beach_Medical_Campus\"><\/span><strong>Hung Family&#8217;s Generous Support Brings Advanced 3T MRI Technology to MemorialCare&#8217;s Long Beach Medical Campus&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 29 July 2026, MemorialCare Long Beach Medical Center expanded its advanced diagnostic imaging capabilities following the acquisition of a new 3-Tesla (3T) magnetic resonance imaging system, supported by a contribution from the Hung family. The installation made the medical campus the only hospital in the greater Long Beach area offering 3T MRI technology at the time. The system provided stronger signal strength and higher-resolution images than conventional MRI, enabling improved visualization of small nerves, ligaments, cartilage, blood vessels, and subtle tissue abnormalities. It also offered patients faster scans, reduced noise, and a wider table for improved comfort. The technology expanded diagnostic capabilities across multiple specialties, including neurology, stroke care, orthopedics, oncology, breast imaging, cardiac imaging, vascular disease, and selected pediatric applications. The higher-resolution imaging further strengthened the hospital\u2019s ability to perform complex neurological, musculoskeletal, cardiac, and vascular examinations. Overall, the addition of the 3T MRI system expanded access to advanced medical imaging, supported more precise diagnoses, and strengthened the adoption of high-field MRI technology in the U.S. medical imaging market.<\/p>\n\n\n\n<p><em>&#8220;The 3T MRI technology gives us the level of image detail needed to evaluate complex conditions with greater clarity and confidence,&#8221; said Nirav Patel, M.D., neurologist, MemorialCare Neuroscience Institute, Long Beach Medical Center. &#8220;For our community physician partners, this means more timely access to advanced imaging that can help inform diagnosis, guide treatment decisions and move patients more efficiently to the next step in their care. It also supports stronger clinical collaboration between referring physicians and specialists, helping ensure patients receive coordinated, high-quality care.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/magnetic-resonance-imaging-devices-market\"><strong>Magnetic Resonance Imaging (MRI) Devices&nbsp; Market Report<\/strong><\/a>\u201d, the magnetic resonance imaging devices market was valued at <strong>USD 8,207.06 million<\/strong> in 2024, growing at a <strong>CAGR of 6.54% <\/strong>during the forecast period from 2025 to 2032 to reach <strong>USD 13,553.33 million<\/strong> by 2032. The rising prevalence of various chronic disorders, such as cardiovascular diseases, cancer, and neurological conditions, is fueling the demand for precise diagnostic tools like MRI, which offers superior imaging capabilities for soft tissues and organs. Additionally, the increasing awareness and the emphasis on early diagnosis of chronic diseases are encouraging patients and healthcare providers to adopt MRI for timely intervention. Furthermore, technological advancements play a crucial role in boosting the MRI market, with innovations such as high-field and open MRI systems, functional MRI (fMRI), and faster scan times improving the accuracy, comfort, and efficiency of the imaging process. Collectively, these factors are expected to expand the demand for magnetic resonance imaging devices globally during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-aqua-medical-treats-first-u-s-patient-for-type-2-diabetes-at-unc-health-using-investigational-through-the-scope-endoscopic-therapy-nbsp\"><span class=\"ez-toc-section\" id=\"Aqua_Medical_Treats_First_US_Patient_for_Type_2_Diabetes_at_UNC_Health_Using_Investigational_Through-The-Scope_Endoscopic_Therapy\"><\/span><strong>Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 28 July 2026, Aqua Medical achieved an important clinical milestone by treating the first U.S. patient in its FDA-authorized Investigational Device Exemption (IDE) trial evaluating its Proximal Intestinal Mucosal Ablation (PIMA) procedure for type 2 diabetes. The procedure was performed at UNC Health in North Carolina and represented the beginning of the company\u2019s U.S. clinical evaluation of its investigational endoscopic metabolic therapy. PIMA used a proprietary radiofrequency vapor ablation platform delivered through the working channel of a standard endoscope to treat a targeted portion of the proximal small intestine. The approach was designed to address abnormal metabolic signaling associated with insulin resistance and promote the restoration of healthier intestinal metabolic signaling. Before initiating the U.S. trial, Aqua Medical had treated 66 patients through its international clinical program, generating safety and clinical data that supported the U.S. study. Unlike conventional interventional approaches, the procedure was performed through a standard endoscope without fluoroscopy and was designed as a minimally invasive outpatient treatment. The clinical trial evaluated the safety and effectiveness of PIMA in adults whose type 2 diabetes remained inadequately controlled despite standard medical therapy. The advancement strengthened the development of minimally invasive, procedure-based treatment options for type 2 diabetes and supported growth opportunities in the endoscopic metabolic therapy and diabetes treatment devices markets.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201d<a href=\"https:\/\/www.delveinsight.com\/report-store\/minimally-invasive-surgical-mis-devices-market\"><strong>Minimally Invasive Surgical Devices Market Report<\/strong><\/a>,\u201d the global minimally invasive surgical devices market is expected to increase from <strong>USD 30,798.01 million<\/strong> in 2025 to <strong>USD 53,259.85 million<\/strong> by 2034, reflecting strong and sustained growth. The global minimally invasive surgical devices market is growing at a <strong>CAGR of 7.13%<\/strong> during the forecast period from 2026 to 2034. The demand for minimally invasive surgical devices is being primarily driven by the rising prevalence of chronic diseases such as cancer and cardiovascular disorders, among others. Additionally, the global increase in the number of surgical procedures being performed using minimally invasive techniques, coupled with growing technological advancements and an increase in product development activities among the key market players, are key factors contributing to the positive growth of the minimally invasive surgical devices market during the forecast period from 2026 to 2034.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-with-neocast-a-next-generation-liquid-embolic-results-in-substantial-chronic-subdural-hematoma-resolution-and-functional-outcome-gains-in-final-embo-02-first-in-human-results-nbsp\"><span class=\"ez-toc-section\" id=\"Treatment_with_NeoCast_a_Next-Generation_Liquid_Embolic_Results_in_Substantial_Chronic_Subdural_Hematoma_Resolution_and_Functional_Outcome_Gains_in_Final_EMBO-02_First-in-Human_Results\"><\/span><strong>Treatment with NeoCast, a Next-Generation Liquid Embolic, Results in Substantial Chronic Subdural Hematoma Resolution and Functional Outcome Gains in Final EMBO-02 First-in-Human Results&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 22 July 2026, Arsenal Medical announced the final first-in-human results from its EMBO-02 clinical trial, demonstrating that treatment with its next-generation liquid embolic agent, NeoCast\u2122, achieved substantial resolution of chronic subdural hematomas (cSDH) while significantly improving patients&#8217; functional outcomes. The study also reported favorable safety and feasibility outcomes, supporting NeoCast&#8217;s potential as an advanced embolic material for middle meningeal artery embolization in the treatment of cSDH. These findings reinforced the promise of NeoCast as a differentiated liquid embolic technology for neurovascular interventions and supported its continued clinical development.<\/p>\n\n\n\n<p><em>&#8220;These NeoCast results are encouraging in ways that could have meaningful implications for both physicians and patients,&#8221; said Tim Phillips, MBBS, GDSA, FRANZCR, interventional neuroradiologist at the Neuro-Intervention and Imaging Service of Western Australia (NIISwa), Sir Charles Gairdner Hospital in Perth, Western Australia, and an investigator in the EMBO-02 study. &#8220;In my experience, NeoCast demonstrated highly predictable distal penetration, allowing effective embolization without the need to advance the microcatheter deep into the target vasculature, which simplified and streamlined the procedure. Equally important, because NeoCast is free of toxic solvents, patients experienced a virtually pain-free injection. The ability to perform middle meningeal artery embolization without sedation represents a meaningful advancement in patient care.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/neurovascular-embolization-devices-market\"><strong>Neurovascular Embolization Devices Market Report<\/strong><\/a>,\u201d the neurovascular embolization devices market was valued at <strong>USD 1,347.66 million<\/strong> in 2024, growing at a <strong>CAGR of 4.40%<\/strong> during the forecast period from 2025 to 2032, to reach <strong>USD 1,890.84 million<\/strong> by 2032. The rising prevalence of neurovascular disorders such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes is significantly driving the global market for neurovascular embolization devices. These conditions often require precise, minimally invasive treatments, for which embolization devices are critical. Additionally, the global increase in hypertension, a major risk factor for neurovascular diseases, has led to a higher incidence of brain hemorrhages and aneurysms, further fueling demand for effective embolization solutions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure&#8217;s FDA Clearance of ProSense\u00ae&nbsp; On 29 July 2026, the Society of Interventional Oncology (SIO) submitted a formal petition to the National Comprehensive Cancer Network (NCCN) seeking the inclusion of percutaneous cryoablation without surgical excision as a Category 2B treatment option for [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35889,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[10106,22956,21219,19331,17021,16975,19869,22419],"industry":[17226],"therapeutic_areas":[17278],"class_list":["post-35887","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-artificial-intelligence-in-healthcare","tag-cryoablation-devices","tag-hemodialysis-machines","tag-magnetic-resonance-imaging-devices","tag-medical-devices-market","tag-medtech-market","tag-minimally-invasive-surgical-devices","tag-neurovascular-embolization-devices","industry-medical-devices","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MedTech News | Nipro Corporation, Akido, Aqua Medical<\/title>\n<meta name=\"description\" content=\"SIO Petitions for Cryoablation; NIPRO\u2019s ELISIO\u2122-HX; Akido\u2019s AI-Native Health System; Aqua Medical\u2019s Through-The-Scope Endoscopic Therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Nipro Corporation, Akido, Aqua Medical\" \/>\n<meta property=\"og:description\" content=\"SIO Petitions for Cryoablation; NIPRO\u2019s ELISIO\u2122-HX; Akido\u2019s AI-Native Health System; Aqua Medical\u2019s Through-The-Scope Endoscopic Therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:29:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:29:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Nipro Corporation, Akido, Aqua Medical","description":"SIO Petitions for Cryoablation; NIPRO\u2019s ELISIO\u2122-HX; Akido\u2019s AI-Native Health System; Aqua Medical\u2019s Through-The-Scope Endoscopic Therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Nipro Corporation, Akido, Aqua Medical","og_description":"SIO Petitions for Cryoablation; NIPRO\u2019s ELISIO\u2122-HX; Akido\u2019s AI-Native Health System; Aqua Medical\u2019s Through-The-Scope Endoscopic Therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-07-30T12:29:03+00:00","article_modified_time":"2026-07-30T12:29:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"SIO Urges NCCN to Add Cryoablation to Breast Cancer Guidelines Following ProSense\u00ae FDA Clearance; NIPRO CORPORATION Secures FDA 510(k) Clearance for ELISIO\u2122-HX HDs in the US; Akido Unveils the First AI-Native Health System in the U.S.; MemorialCare Enhances Diagnostic Imaging with Hung Family-Funded 3T MRI Technology; Aqua Medical Treats First U.S. Type 2 Diabetes Patient at UNC Health with Investigational Endoscopic Therapy; NeoCast Delivers Robust Hematoma Resolution and Functional Recovery in Final EMBO-02 First-in-Human Results","datePublished":"2026-07-30T12:29:03+00:00","dateModified":"2026-07-30T12:29:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical"},"wordCount":2322,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical.webp","keywords":["Artificial intelligence in healthcare","Cryoablation Devices","Hemodialysis Machines","Magnetic Resonance Imaging Devices","Medical Devices Market","MedTech Market","Minimally Invasive Surgical Devices","Neurovascular Embolization Devices"],"articleSection":["Notizia - Recent Pharma, Healthcare and Biotech Happenings"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical","name":"MedTech News | Nipro Corporation, Akido, Aqua Medical","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical.webp","datePublished":"2026-07-30T12:29:03+00:00","dateModified":"2026-07-30T12:29:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"SIO Petitions for Cryoablation; NIPRO\u2019s ELISIO\u2122-HX; Akido\u2019s AI-Native Health System; Aqua Medical\u2019s Through-The-Scope Endoscopic Therapy","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-nipro-akido-aqua-medical#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical.webp","width":772,"height":482,"caption":"medtech-news-for-nipro-akido-aqua-medical"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-nipro-akido-aqua-medical-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Artificial intelligence in healthcare<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cryoablation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hemodialysis Machines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Magnetic Resonance Imaging Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Minimally Invasive Surgical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurovascular Embolization Devices<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Artificial intelligence in healthcare<\/span>","<span class=\"advgb-post-tax-term\">Cryoablation Devices<\/span>","<span class=\"advgb-post-tax-term\">Hemodialysis Machines<\/span>","<span class=\"advgb-post-tax-term\">Magnetic Resonance Imaging Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Minimally Invasive Surgical Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurovascular Embolization Devices<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 minutes ago","modified":"Updated 6 minutes ago"},"absolute_dates":{"created":"Posted on Jul 30, 2026","modified":"Updated on Jul 30, 2026"},"absolute_dates_time":{"created":"Posted on Jul 30, 2026 5:59 pm","modified":"Updated on Jul 30, 2026 5:59 pm"},"featured_img_caption":"medtech-news-for-nipro-akido-aqua-medical","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35887"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35887\/revisions"}],"predecessor-version":[{"id":35888,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35887\/revisions\/35888"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35889"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35887"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35887"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}